Facebook
X
LinkedIn
Forward
The Latest Breakthroughs in Metastatic Hormone Sensitive Prostate Cancer (2025)
In response to critical insights from the American Urological Association's (AUA) Advanced Prostate Cancer Global Needs Assessment, the AUA proud to present The Latest Breakthroughs in Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
This dynamic program will feature a live virtual panel discussion with leading experts, exploring cutting-edge developments in mHSPC treatment and offering practical insights for clinical application. Whether you’re a urologist, resident, or advanced practice provider, this course will equip you with the knowledge needed to deliver optimal, evidence-based care in a rapidly evolving landscape.
This multi-format learning experience includes:
- A Live Virtual Webinar featuring a multidisciplinary expert panel in a lively, interactive discussion on the latest clinical advances in mHSPC
- An On-Demand Webcast available via AUAUniversity and the AUAUniversity YouTube channel for convenient access anytime, for up to one year
- A Podcast Episode released as part of the highly successful AUAUniversity Podcast series
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
- AstraZeneca
- Bayer HealthCare Pharmaceuticals Inc.
Target Audience
- Urologists
- APPs
- Residents/Fellows
Learning Objectives
After participating in this CME activity, participants will be able to:
- Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC.
- Implement current clinical guidelines for biomarker testing in mHSPC.
- Explain the role of the PI3K/AKT pathway in prostate cancer biology.
- Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC.
- Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC.